Comparison of Therapeutic Effects of Different Mesenchymal Stem Cells on Rheumatoid Arthritis in Mice

Overview

Journal PeerJ

Specialties Biology
Environmental Health
General Medicine

Date 2019 Jun 15

PMID 31198641

Citations 27

Authors

Qing Zhang

Qihong Li

Jun Zhu

Hao Guo

Qiming Zhai

Bei Li

Yan Jin

Xiaoning He

Fang Jin

Affiliations

Soon will be listed here.

Abstract

Background: Rheumatoid arthritis (RA) is a chronic and nonspecific autoimmune disease, which leads to joint destruction and deformity. To investigate the potential of human mesenchymal stem cells (MSCs) as a new therapeutic strategy for patients with RA, we compared the therapeutic effects of bone marrow derived MSCs (BMSCs), umbilical cord derived MSCs (UCs), and stem cells derived from human exfoliated deciduous teeth (SHED) on collagen-induced arthritis (CIA) in mice.

Methods: A total of 24 DBA/1 mice were infused with type II collagen to induce RA in the experimental model. MSC-treated mice were infused with UCs, BMSCs, and SHED, respectively. Bone erosion and joint destruction were measured by micro-computed tomographic (micro-CT) analysis and hematoxylin and eosin staining. The levels of tumor necrosis factor α (TNF-α) and interleukin-1β (IL-1β) were measured by immunohistochemistry and Enzyme-Linked Immunosorbent Assay (ELISA).

Results: Systemic delivery of MSCs significantly improved the severity of the symptoms related to CIA to greater extent compared with the untreated control group. Micro-CT revealed reduced bone erosions in the metatarsophalangeal joints upon treatment with MSCs. Additionally, according to histologic evaluation, reduced synovitis and articular destruction were observed in MSC-treated groups. The levels of TNF-α and IL-1β in the serum and joints decreased with treatment by MSCs.

Conclusion: Our findings suggest that systemic infusion of UCs, BMSCs, and SHED may significantly alleviate the effects of RA. The therapeutic effect of BMSCs was greater than that of SHED, while the UCs were shown to have the best therapeutic effect on CIA mice. In conclusion, compared with BMSCs and SHED, UCs may be a more suitable source of MSCs for the treatment of patients with RA.

Citing Articles

Exploring perinatal mesenchymal stromal cells as a potential therapeutic strategy for rheumatoid arthritis.

Alivernini S, Masserdotti A, Magatti M, Cargnoni A, Papait A, Silini A Heliyon. 2025; 11(1):e41438.

PMID: 39811302 PMC: 11732555. DOI: 10.1016/j.heliyon.2024.e41438.

Potential use of stem cell therapies for treating osteoarthritis and rheumatoid arthritis.

Esquivel D, Mishra R, Srivastava A Ann Transl Med. 2024; 12(4):72.

PMID: 39118961 PMC: 11304433. DOI: 10.21037/atm-23-1951.

Exosomes and exosomal miRNAs: A new avenue for the future treatment of rheumatoid arthritis.

Liu Y, Jiang P, Qu Y, Liu C, Zhang D, Xu B Heliyon. 2024; 10(6):e28127.

PMID: 38533025 PMC: 10963384. DOI: 10.1016/j.heliyon.2024.e28127.

Human umbilical cord/placenta mesenchymal stem cell conditioned medium attenuates intestinal fibrosis in vivo and in vitro.

Choi Y, Kim W, Kim D, Kim J, Yoo J Stem Cell Res Ther. 2024; 15(1):69.

PMID: 38454492 PMC: 10921617. DOI: 10.1186/s13287-024-03678-4.

Mesenchymal Stromal Cells Derived from Dental Tissues: Immunomodulatory Properties and Clinical Potential.

Poblano-Perez L, Castro-Manrreza M, Gonzalez-Alva P, Fajardo-Orduna G, Montesinos J Int J Mol Sci. 2024; 25(4).

PMID: 38396665 PMC: 10888494. DOI: 10.3390/ijms25041986.

References

Young D, Lawlor P, Leone P, Dragunow M, During M . Environmental enrichment inhibits spontaneous apoptosis, prevents seizures and is neuroprotective. Nat Med. 1999; 5(4):448-53. DOI: 10.1038/7449. View

Fox D . Cytokine blockade as a new strategy to treat rheumatoid arthritis: inhibition of tumor necrosis factor. Arch Intern Med. 2000; 160(4):437-44. DOI: 10.1001/archinte.160.4.437. View

Lam J, Takeshita S, Barker J, Kanagawa O, Ross F, Teitelbaum S . TNF-alpha induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand. J Clin Invest. 2000; 106(12):1481-8. PMC: 387259. DOI: 10.1172/JCI11176. View

Rao M, Mattson M . Stem cells and aging: expanding the possibilities. Mech Ageing Dev. 2001; 122(7):713-34. DOI: 10.1016/s0047-6374(01)00224-x. View

Di Nicola M, Carlo-Stella C, Magni M, Milanesi M, Longoni P, Matteucci P . Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood. 2002; 99(10):3838-43. DOI: 10.1182/blood.v99.10.3838. View

Abramson S, Amin A . Blocking the effects of IL-1 in rheumatoid arthritis protects bone and cartilage. Rheumatology (Oxford). 2002; 41(9):972-80. DOI: 10.1093/rheumatology/41.9.972. View

Mitchell K, Weiss M, Mitchell B, Martin P, Davis D, Morales L . Matrix cells from Wharton's jelly form neurons and glia. Stem Cells. 2003; 21(1):50-60. DOI: 10.1634/stemcells.21-1-50. View

Miura M, Gronthos S, Zhao M, Lu B, Fisher L, Robey P . SHED: stem cells from human exfoliated deciduous teeth. Proc Natl Acad Sci U S A. 2003; 100(10):5807-12. PMC: 156282. DOI: 10.1073/pnas.0937635100. View

Hyrich K, Silman A, Watson K, Symmons D . Anti-tumour necrosis factor alpha therapy in rheumatoid arthritis: an update on safety. Ann Rheum Dis. 2004; 63(12):1538-43. PMC: 1754871. DOI: 10.1136/ard.2004.024737. View

10.

Glennie S, Soeiro I, Dyson P, Lam E, Dazzi F . Bone marrow mesenchymal stem cells induce division arrest anergy of activated T cells. Blood. 2004; 105(7):2821-7. DOI: 10.1182/blood-2004-09-3696. View

11.

Djouad F, Fritz V, Apparailly F, Louis-Plence P, Bony C, Sany J . Reversal of the immunosuppressive properties of mesenchymal stem cells by tumor necrosis factor alpha in collagen-induced arthritis. Arthritis Rheum. 2005; 52(5):1595-603. DOI: 10.1002/art.21012. View

12.

Corcione A, Benvenuto F, Ferretti E, Giunti D, Cappiello V, Cazzanti F . Human mesenchymal stem cells modulate B-cell functions. Blood. 2005; 107(1):367-72. DOI: 10.1182/blood-2005-07-2657. View

13.

Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D . Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 2006; 8(4):315-7. DOI: 10.1080/14653240600855905. View

14.

Sato K, Ozaki K, Oh I, Meguro A, Hatanaka K, Nagai T . Nitric oxide plays a critical role in suppression of T-cell proliferation by mesenchymal stem cells. Blood. 2006; 109(1):228-34. DOI: 10.1182/blood-2006-02-002246. View

15.

Brand D, Latham K, Rosloniec E . Collagen-induced arthritis. Nat Protoc. 2007; 2(5):1269-75. DOI: 10.1038/nprot.2007.173. View

16.

Bradley J . TNF-mediated inflammatory disease. J Pathol. 2007; 214(2):149-60. DOI: 10.1002/path.2287. View

17.

Stolzing A, Jones E, McGonagle D, Scutt A . Age-related changes in human bone marrow-derived mesenchymal stem cells: consequences for cell therapies. Mech Ageing Dev. 2008; 129(3):163-73. DOI: 10.1016/j.mad.2007.12.002. View

18.

Noh E, Kim J, Hur H, Park B, Song E, Han M . Cordycepin inhibits IL-1beta-induced MMP-1 and MMP-3 expression in rheumatoid arthritis synovial fibroblasts. Rheumatology (Oxford). 2008; 48(1):45-8. DOI: 10.1093/rheumatology/ken417. View

19.

Nemeth K, Leelahavanichkul A, Yuen P, Mayer B, Parmelee A, Doi K . Bone marrow stromal cells attenuate sepsis via prostaglandin E(2)-dependent reprogramming of host macrophages to increase their interleukin-10 production. Nat Med. 2008; 15(1):42-9. PMC: 2706487. DOI: 10.1038/nm.1905. View

20.

Kastrinaki M, Papadaki H . Mesenchymal stromal cells in rheumatoid arthritis: biological properties and clinical applications. Curr Stem Cell Res Ther. 2009; 4(1):61-9. DOI: 10.2174/157488809787169084. View